Skip to main content

This information is for the use of medical researchers and persons interested in health sciences. It must be emphasized that GHK and other copper binding peptides have not been tested on human cancers and are not approved for such uses.


In 1983 an article by Linus Pauling's group found that a copper peptide very similar to GHK gave a strong tumor inhibition when administered with Vitamin C. The non-toxic procedure either extended the lifespan of tumor-bearing mice or killed the tumors. All of the untreated tumor-bearing mice died. 60% of the treated mice lived twice as long as the tumor-only mice and 40% appeared to have been cured of the cancer. The tumor could not be re-implanted in the surviving mice and the paper said "...the mice lived a for a long period."


In 1986, Dr. Pickart repeated the Pauling anti-cancer treatment in mice but with GHK-copper and vitamin C. The mice were implanted with fibrosarcoma cells which grow as a solid mass in the thigh muscles. After 5 days, the mice were injected intraperitoneally with GHK-copper and Vitamin C with the Pauling dosage three times per week (Mon, Wed, Fri) for 2 weeks. Then the experiment was stopped at 6 weeks.

There was a strong inhibition of tumor growth (about -70%) and some of the mice appeared to have no tumors. The injected copper peptides and vitamin C appeared to have no negative effect on the mice's behavior or physical condition.


Unfortunately, Dr. Pickart was unable to obtain funding to extend this work from the National Cancer Institute. The Review Panel said such therapies were not needed since new non-toxic biologicals would be used in the near future to cure cancer. However, 26 years later, damaging and poorly effective toxic cancer therapies are still the main treatment.


The full Pauling article is available at no cost at http://cancerres.aacrjournals....nt/43/2/824.full.pdf .

Last edited by skinbiologywebmaster
Original Post

Add Reply

Link copied to your clipboard.